LYRM03 is a derivative of Ubenimex ( HY-B0134 ) and a Aminopeptidase N inhibitor. LYRM03 is isolated from Streptomyces HCCB10043. LYRM03 inhibits TLR4 , MyD88 , NLRP3 , ASC , NF-κB and p38 MAPK , stabilizes IκB , and suppresses LPS-induced expression of iNOS and COX-2 . LYRM03 reduces the levels of inflammatory cytokines and oxidative stress markers, and alleviates pulmonary edema. LYRM03 exhibits anticancer activity against breast cancer . LYRM03 has anti-inflammatory activity. LYRM03 can be used in the research of acute lung injury and breast cancer .
Products | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Pulmonary Disease | Products > Disease Areas > Respiratory Inflammation | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Acute Lung Injury | Products > Signaling Pathways > Others | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Toll-like Receptor (TLR) | Products > Signaling Pathways > MyD88 | Products > Signaling Pathways > NOD-like Receptor (NLR) | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > p38 MAPK | Products > Signaling Pathways > IKK | Products > Signaling Pathways > NO Synthase | Products > Signaling Pathways > COX | Products > Signaling Pathways > Drug Derivative | Products > Signaling Pathways > Aminopeptidase | Products > Signaling Pathways > Endogenous Metabolite
感谢您来到爆牛贸易,请为我们留言或者使用以下方式联系我们,我们将尽快给您回复,并为您提供最真诚的服务,谢谢。